Share prices (live or delayed, as supplied by TradingView) for the listed companies that make spine implants, biologics and enabling technology, in one dashboard.
Live prices on requestDelayed ~15 minNot investment advice
Listings are a selection made at NSpine's editorial discretion and are not exhaustive. Inclusion is not an endorsement, and omission implies nothing.
Live prices are switched off until you choose to load them.Clicking to load the charts allows third-party cookies from TradingView. The charts come from TradingView, a third-party service based in the US. Loading them connects your browser to TradingView, which receives your IP address and device information and may set cookies. Without it, the company list, descriptions and links below all work. See the privacy notice.
PricesDelayedMost exchanges about 15 minutes behind
List reviewed25 October 2026Companies checked monthly
Market overview
5 November 2026Globus Medical third-quarter resultsThe largest spine specialist reports its third-quarter results, usually the first read on how the spine market did over the summer.
OngoingThe future of DePuy SynthesJ&J plans to separate its orthopaedics business. In September Bloomberg reported talks on a sale to Apollo of about $20 billion; nothing had been signed by then. If it is sold privately, DePuy Synthes spine leaves the stock market.
ContextMany spine leaders are privateB. Braun (Aesculap), ulrich medical, SIGNUS, VB Spine (which bought Stryker's US spine business in 2025), Highridge Medical (formerly Zimmer Biomet spine) and Zavation, which bought ChoiceSpine in 2026, have no listed shares.
Company dashboard
Each company has a News tab, refreshed monthly, with company news that may matter for the share price. We do not publish analyst ratings or price targets. Nothing on this page is investment advice or an endorsement by NSpine; some sources are paywalled.
Globus Medical
NYSE · GMED
Spine specialists
ImplantsRoboticsNeuromodulation
The largest spine specialist. Merged with NuVasive in 2023 and bought Nevro (spinal cord stimulation) in 2025; ExcelsiusGPS robot.
News 5 items
Company news that may matter for the share price: results, deals, approvals, recalls and leadership changes. Not investment advice and not an endorsement by NSpine. Summaries are ours; the full story is at the source.
News
Q3 sales slightly down; 2026 revenue guidance cut. Globus reported Q3 2026 net sales of $763.7 million, down 0.7% year on year, with non-GAAP diluted EPS of $1.23. It lowered 2026 revenue guidance to $3.09 billion (from $3.18-3.22 billion), kept non-GAAP EPS guidance of $4.95-5.05 and added $500 million to its share buyback. Company release (SEC 8-K) ↗
Globus previews SCRIPT patient-specific implants and XLIF prone kit at NASS. At NASS 2026 (San Antonio, 14-17 Oct) Globus previewed SCRIPT, its FDA-cleared patient-specific spinal implant platform with surgeon-controlled planning that links to ExcelsiusGPS. It also showed an XLIF prone lateral package with a new positioner and two-blade retractor. Company release ↗
Q3 results date set. Globus will report third-quarter 2026 results after the market closes on 5 November 2026, followed by a 4:30 pm ET call. Company release ↗
Excelsius3D imaging system gains CE mark. The mobile intraoperative imaging platform (cone-beam CT, fluoroscopy and radiography) is now CE marked for sale in the EU and UK. It works with the ExcelsiusGPS robot or as a stand-alone system and has had US 510(k) clearance since 2021. Company release ↗
Globus buys AI health-software start-up Higgs Boson Health. Globus acquired Durham, NC-based Higgs Boson Health, a Duke University spin-out, to add AI and digital tools to its 'surgical intelligence' offering. Financial terms were not disclosed. Company release ↗
Next: Q3 2026 results reported 5 Nov 2026; next scheduled event not yet announced
Built around lateral and prone transpsoas access, with EOS imaging and its own neuromonitoring and navigation.
News 5 items
Company news that may matter for the share price: results, deals, approvals, recalls and leadership changes. Not investment advice and not an endorsement by NSpine. Summaries are ours; the full story is at the source.
News
Q3 revenue up 13% but below company expectations. ATEC reported Q3 2026 revenue of $221 million, up 13%, and a GAAP net loss of $5.5 million; management said revenue fell short of its expectations, mainly because of lower biologics attachment. Its 2026 outlook is now about $862 million revenue and about $137 million adjusted EBITDA. Company release (SEC 8-K) ↗
New EVP for data intelligence and strategy. ATEC appointed spine-industry executive Tommy Carls as EVP, Data Intelligence and Strategy, to lead its 'InformatiX' data strategy. Company release via Quantisnow ↗
CEO buys about $1 million of shares. SEC Form 4 data show CEO Pat Miles bought 115,000 shares at about $8.81 each, roughly $1.0 million in total. The date is when the filing was posted; the exact trade date was not shown. SEC Form 4 via Quantisnow ↗
Q2 revenue up 15%, outlook reaffirmed. ATEC reported Q2 2026 revenue of $214 million, up 15% year on year, and reaffirmed its 2026 revenue outlook. Company release via Quantisnow ↗
Next: Q3 2026 results reported 29 Oct 2026; next scheduled event not yet announced
Merged with SeaSpine in 2023: spinal implants, biologics, bone growth stimulators, 7D navigation and limb reconstruction.
News 2 items
Company news that may matter for the share price: results, deals, approvals, recalls and leadership changes. Not investment advice and not an endorsement by NSpine. Summaries are ours; the full story is at the source.
News
Q2 net sales up 3.8%. Q2 2026 net sales were $210.9 million (up 3.8%). Limb reconstruction grew 13.2%, while spinal implants/biologics/enabling technologies (+1.7%) and bone-growth therapies (+2.5%) grew slowly. SEC 10-Q (Q2 2026) ↗
Legacy executive disputes largely resolved. Per the Q2 10-Q, Orthofix paid about $14.8 million on an arbitration award to its former CEO and settled with two other former executives for $4.25 million each. A securities class action is still pending after a partial dismissal. SEC 10-Q (Q2 2026) ↗
Next: Q3 2026 results 9 Nov 2026, before market open, 8:30 am ET call (company announcement via quantisnow.com/earnings/OFIX)
Patient-specific, 3D-printed interbody implants planned from the patient's own imaging (aprevo). Listed since 2025.
News 3 items
Company news that may matter for the share price: results, deals, approvals, recalls and leadership changes. Not investment advice and not an endorsement by NSpine. Summaries are ours; the full story is at the source.
News
US launch of aprevo bilateral posterior system. At NASS, Carlsmed began the US commercial launch of its personalised aprevo Lumbar Bi-lateral Posterior system. Company release via Quantisnow ↗
New CFO and new Chief Product and AI Officer. Richard Heppenstall succeeds Leo Greenstein as CFO. Tony Jarc was named to the newly created role of Chief Product and AI Officer on 1 October. Company releases via Quantisnow ↗
Patent suit filed against DeGen Medical. Carlsmed sued DeGen Medical, alleging infringement of eight patents. The court and accused products were not shown in the excerpt. Company release via Quantisnow ↗
Next: Q3 2026 results 10 Nov 2026, after market close, 1:30 pm PT call (company release via BioPharmaWatch)
Paediatric orthopaedics only, including scoliosis fusion and non-fusion systems such as ApiFix.
News 6 items
Company news that may matter for the share price: results, deals, approvals, recalls and leadership changes. Not investment advice and not an endorsement by NSpine. Summaries are ours; the full story is at the source.
News
Q3 revenue up 19%, 2026 revenue guidance raised. OrthoPediatrics reported Q3 2026 revenue of $72.7 million, up 19%, a smaller net loss of $5.9 million and record adjusted EBITDA of $6.9 million. It raised 2026 revenue guidance to $270-273 million (from $265-269 million). Company release (SEC 8-K) ↗
Q3 results date set. Q3 2026 results are due after the market closes on 27 October 2026, with a 4:30 pm ET call. Company release via Finviz ↗
Knee bracing line expanded. OrthoPediatrics launched the OPSB Knee 'TractorFIX' brace, adding to its lower-limb bracing range. Company release via Quantisnow ↗
Major shareholder sells shares. Form 4 filings show that large holder Squadron Capital (linked to director David Pelizzon and Jennifer Pritzker) sold blocks of shares in September, including 302,369 shares at $21.01 (about $6.4 million). SEC Form 4 via Quantisnow ↗
Full launch of 3P paediatric hip plating system. OrthoPediatrics moved its 3P Pediatric Plating Platform Hip System to full commercial launch after more than 350 implantations. Company release via Quantisnow ↗
iFuse implants for sacroiliac joint fusion, plus pelvic fixation and pelvic trauma systems.
News 3 items
Company news that may matter for the share price: results, deals, approvals, recalls and leadership changes. Not investment advice and not an endorsement by NSpine. Summaries are ours; the full story is at the source.
News
Q3 results date set. SI-BONE will report Q3 2026 results after the market closes on 2 November 2026, with a 4:30 pm ET call. Company release via BioPharmaWatch ↗
FDA clears iFuse Granite Onyx. The 510(k) clearance covers SI-BONE's first product for compromised bone outside the pelvis, taking its compromised-bone franchise beyond the SI joint. Company release via Quantisnow ↗
Q2 revenue up 15%, guidance raised. SI-BONE reported Q2 2026 worldwide revenue of $56.0 million (up 15.2%) and raised its 2026 guidance. Company release via Quantisnow ↗
Next: Q3 2026 results reported 2 Nov 2026; next scheduled event not yet announced
A single-product micro-cap: the Catamaran system for SI joint fusion. Small and volatile.
News 5 items
Company news that may matter for the share price: results, deals, approvals, recalls and leadership changes. Not investment advice and not an endorsement by NSpine. Summaries are ours; the full story is at the source.
News
Q3 results date set. Tenon will report third-quarter 2026 results after the market closes on 12 November 2026, followed by a 4:30 pm ET call. Company release via Value The Markets ↗
Eight new US patents. Eight newly issued US patents bring Tenon's portfolio to 38 US patents (plus international patents) covering sacropelvic fusion. Company release via Quantisnow ↗
Full launch of SImmetry+ 3D-printed SI screw. After a limited launch that brought in about $1.2 million of extra revenue, Tenon moved its SImmetry+ 3D-printed lateral SI-joint fusion screw to full commercial launch. Company release via Quantisnow ↗
Warrant inducement raises about $2.9 million. Tenon closed a warrant inducement deal with an institutional investor for gross proceeds of about $2.87 million. Company release via Quantisnow ↗
Convertible notes repaid early. Tenon repaid its original-issue-discount senior convertible notes (about $5.2 million principal) before maturity, saying the aim was to strengthen its balance sheet. Company release via Quantisnow ↗
Next: Q3 2026 results 12 Nov 2026, after market close, 4:30 pm ET call (company release)
Bone graft biologics (allograft and synthetics) alongside a spinal implant range.
News 2 items
Company news that may matter for the share price: results, deals, approvals, recalls and leadership changes. Not investment advice and not an endorsement by NSpine. Summaries are ours; the full story is at the source.
News
Dental partnership with BioHorizons. BioHorizons (a Henry Schein company) gained exclusive rights to sell Xtant's OsteoFactor Pro allogeneic growth factor in dentistry under its own brand, Prolifica BELGRA. Company release via Quantisnow ↗
Q2 results and Trivium Shaped launch. Xtant reported Q2 2026 revenue of $23.0 million and launched Trivium Shaped, an extension of its demineralised bone matrix allograft line. Company release via Quantisnow ↗
Swiss maker of MagnetOs, a synthetic bone graft used mainly in spinal fusion.
News 3 items
Company news that may matter for the share price: results, deals, approvals, recalls and leadership changes. Not investment advice and not an endorsement by NSpine. Summaries are ours; the full story is at the source.
News
MagnetOs production begins in Alpharetta, USA. Commercial production of the MagnetOs bone graft has started at Kuros's new US headquarters in Alpharetta, Georgia (as reported by Börse Global). Börse Global ↗
Nine-month sales up 40%; 2026 guidance raised. Nine-month medical device sales rose 40% to USD 141.8 million and adjusted EBITDA rose 68% to USD 20.6 million. Kuros raised its 2026 guidance to 36-40% sales growth and an adjusted EBITDA margin above 14.5% (as reported by Finanztrends; the company release was not opened). Finanztrends.de ↗
H1 sales up 45%, first half-year profit. Kuros reported H1 2026 medical device sales of USD 92.4 million (up 45%), adjusted EBITDA of USD 12.5 million and net profit of USD 4.4 million. It confirmed its 2026 guidance of at least 35% growth and its 2028 targets. Company release ↗
French spine implant maker near Lyon, selling mainly outside France. Very small and thinly traded.
News 1 item
Company news that may matter for the share price: results, deals, approvals, recalls and leadership changes. Not investment advice and not an endorsement by NSpine. Summaries are ours; the full story is at the source.
News
Nine-month revenue down 7% on supply problems. Spineway's nine-month 2026 revenue was EUR 8.0 million (down 7%) and Q3 revenue was EUR 2.3 million (down 25%). The company blamed supply problems at some subcontractors. Asia grew 27% and Latin America fell 33%. Company release via 24matins ↗
Next: FY 2026 revenue 26 Jan 2027 (company release)
Small US company listed in Canada: interspinous fixation, SI joint and density-matched DEXA implants.
News 1 item
Company news that may matter for the share price: results, deals, approvals, recalls and leadership changes. Not investment advice and not an endorsement by NSpine. Summaries are ours; the full story is at the source.
News
Q2 FY26 revenue down 19%. Aurora Spine's Q2 revenue was USD 3.66 million (down 18.7%), with a net loss of USD 0.83 million, as SI-joint sales fell while sales of DEXA-C cervical implants rose 66%. The company is restructuring its sales team and gave no formal guidance. Company release (Newsfile) ↗
Spine sits in its Neuroscience division (Cranial & Spinal Technologies): implants, Mazor robot, StealthStation, Infuse.
News 1 item
Company news that may matter for the share price: results, deals, approvals, recalls and leadership changes. Not investment advice and not an endorsement by NSpine. Summaries are ours; the full story is at the source.
News
Q1 FY27: Cranial & Spinal Technologies up 13%. Medtronic's Q1 FY27 revenue rose 13.7% to $9.76 billion. Cranial & Spinal Technologies grew 12.8% to $1.37 billion, helped by growth in the low 20s % in enabling technology. Full-year guidance for organic growth and EPS was raised. Company release ↗
Next: Q2 FY27 results expected mid/late Nov 2026; date not yet announced
Spine is part of DePuy Synthes. J&J announced plans to separate DePuy Synthes in 2025; sale talks with Apollo were reported in September 2026.
News 3 items
Company news that may matter for the share price: results, deals, approvals, recalls and leadership changes. Not investment advice and not an endorsement by NSpine. Summaries are ours; the full story is at the source.
News
Smith & Nephew combination talks reportedly failed. The Financial Times reported that talks to combine DePuy Synthes with Smith & Nephew broke down over who would lead the merged company (as summarised by TIKR). TIKR (citing Financial Times) ↗
Q3: MedTech up 2.5%; orthopaedics separation still planned. J&J's Q3 2026 sales rose 5.9% to $25.4 billion, with MedTech up 2.5% to $8.64 billion, and full-year guidance was nudged up. Orthopaedics (DePuy Synthes) figures were not broken out in the release. Company release (SEC 8-K) ↗
CFO says J&J is 'leaning towards a spin' of DePuy Synthes. On the Q3 call, CFO Joe Wolk said a spin-off is the preferred route for the orthopaedics business, with separation on track for mid-2027 (as reported by TIKR). Bloomberg had reported in September that J&J had discussed a roughly $20 billion deal with Apollo. TIKR (citing earnings call and Bloomberg) ↗
Next: Enterprise Business Review 8 Dec 2026, with an expected separation pro forma and 2027 outlook (per CFO, reported by TIKR)
Choose a company above the chart to switch, and a time range below it. Share prices are in each exchange's currency.
How we compile this page
Summarised, never copied. Every item is written in our own words and links to the original patent, paper or announcement.
Selected by published rules. Each section covers what is new in its field. Searches and first drafts use AI assistance and are checked against the sources.
A surgeon's view. Each month a clinical guest editor picks what matters across the site, and a research guest editor chooses up to ten papers to read first.
Independent of sponsors. NSpine works with industry for its courses. Sponsors have no say in what Spinal Frontiers covers. Read the policy.
Spinal Frontiers is published by NSpine Limited, registered in England and Wales (company no. 08362634), 14 Park Row, Nottingham NG1 6GR, United Kingdom. Every item is summarised in our own words and links to its original source. Listings are a selection made at NSpine's editorial discretion and are not exhaustive; inclusion is not an endorsement, and omission implies nothing. Sponsors and advertisers have no influence on what we cover. Nothing here is medical, legal or financial advice. Spotted an error or a broken link? Email spinalfrontiers@nspine.com, or use the feedback page.
Spinal Frontiers is a trademark of NSpine GmbH.
Information only, summarised from third-party sources: not medical, legal, regulatory or financial advice. Full disclaimer.
Spinal FrontiersPowered by NSpine